Inactive Instrument

Kadmon Holdings, Inc.

KDMN

US48283N1063

Kadmon Holdings, Inc Announces the Resignation of Lawrence K. Cohen as Executive Vice President, Research and Business Development Effective October 20, 2017

October 06, 2017 at 09:52 pm

On October 2, 2017 Kadmon Holdings, Inc. announced Dr. Lawrence K. Cohen informed that he will resign from the company as Executive Vice President, Research and Business Development, to pursue other opportunities. Dr. Cohen's resignation is effective on October 20, 2017.

Latest news about Kadmon Holdings, Inc.

Sanofi in $1 bln deal to buy U.S.-based Amunix Pharma	21/12/21	RE
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P Global BMI Index	10/11/21	CI
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P TMI Index	10/11/21	CI
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P Biotechnology Select Industry Index	10/11/21	CI
Sanofi Closes on Kadmon Acquisition	09/11/21	MT
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Composite Index	09/11/21	CI
Sanofi completed the acquisition of Kadmon Holdings, Inc..	08/11/21	CI
Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Biotechnology Index	08/11/21	CI
Kadmon Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	04/11/21	CI
Earnings Flash (KDMN) KADMON HOLDINGS Reports Q3 Revenue $14.7M	04/11/21	MT
Kadmon : Health Care Stocks Edging Higher At Close	21/10/21	MT
Sector Update: Health Care	21/10/21	MT
Kadmon : Announces Expiration of HSR Waiting Period in Sanofi Deal	21/10/21	MT
North American Morning Briefing : Stock Futures -3-	15/09/21	DJ
KADMON : Mizuho Securities Downgrades Kadmon Holdings to Neutral from Buy, Adjusts Price Target to $9.50 from $13	14/09/21	MT
KADMON : UBS Downgrades Kadmon Holdings to Neutral From Buy, Adjusts PT to $9.50 From $9	10/09/21	MT
North American Morning Briefing : Stock Futures -3-	10/09/21	DJ
KADMON : Oppenheimer Suspends Rating for Kadmon Holdings Following Sanofi Merger	09/09/21	MT
KADMON : Jefferies Downgrades Kadmon Holdings to Hold from Buy, Adjusts Price Target to $9.50 from $10	09/09/21	MT
ADRs End Lower; Nio, Sanofi Among Companies Actively Trading	08/09/21	DJ
Health Care Flat On Defensive Bias -- Health Care Roundup	08/09/21	DJ
Alector : Health Care Stocks Edging Lower Just Ahead of Wednesday Close	08/09/21	MT
Flora Growth : Health Care Stocks Fighting to Overcome Market Downdrafts	08/09/21	MT
Top Midday Gainers	08/09/21	MT
Stoxx Europe 600 : European Stocks Close Lower Amid Economic Growth Concerns, Rising COVID-19 Cases	08/09/21	MT

Chart Kadmon Holdings, Inc.

Duration

Period

More charts

Company Profile

Kadmon Holdings, Inc. is a biopharmaceutical company, which is engaged in discovering, developing, and delivering therapies for unmet medical needs. The Company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. It is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The Company has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.49B
BIOGEN INC.	-15.48%	32.79B
UCB	+64.13%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.52B
INCYTE CORPORATION	-7.68%	13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	11.5B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.82B

Biopharmaceuticals